Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 898.95 INR
Change Today +12.50 / 1.41%
Volume 13.9M
SUNP On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 7:06 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

sun pharmaceutical indus (SUNP) Snapshot

Open
882.40
Previous Close
886.45
Day High
909.95
Day Low
870.55
52 Week High
04/7/15 - 1,201
52 Week Low
09/26/14 - 748.00
Market Cap
2.2T
Average Volume 10 Days
5.1M
EPS TTM
21.92
Shares Outstanding
2.4B
EX-Date
--
P/E TM
41.0x
Dividend
3.00
Dividend Yield
0.17%
Current Stock Chart for SUN PHARMACEUTICAL INDUS (SUNP)

Related News

No related news articles were found.

sun pharmaceutical indus (SUNP) Related Businessweek News

View More BusinessWeek News

sun pharmaceutical indus (SUNP) Details

Sun Pharmaceutical Industries Limited, a specialty pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, such as psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics, ophthalmology, diabetology, musculo-skeletal and pain, gynecology, and urology, as well as antiasthamatic and antiallergic. It also provides APIs comprising anticancers, peptides, sex hormones, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is based in Mumbai, India.

Founded in 1983

sun pharmaceutical indus (SUNP) Top Compensated Officers

Managing Director, Executive Director and Mem...
Total Annual Compensation: 23.1M
Wholetime Director and Member of Shareholders...
Total Annual Compensation: 23.1M
Whole Time Director
Total Annual Compensation: 8.5M
Compensation as of Fiscal Year 2014.

sun pharmaceutical indus (SUNP) Key Developments

Sun Pharmaceutical Industries Faces Class Action Suit over Caraco Plant Closure

Sun Pharmaceutical Industries is facing a class action suit over the closure of its Caraco's facility in Michigan six years ago. The company faces charges of violating the Worker Adjustment and Retraining Notification Act, which requires companies to give 60 days' notice before a plant is shut down. The purpose of the law is to provide time for workers, their families and communities to adjust with plant closings and mass layoffs. Advance notice provides workers and their families some transition time to adjust to the prospective loss of employment, to seek and obtain alternative jobs and, if necessary, to enter skill training or retraining that will allow these workers to successfully compete in the job market said the United States District Court that accepted the suit. The case filed by James Calloway, one of the nearly 600 people who were laid off, has alleged that Sun did not adhere to labour laws while shutting the plant. In its defence to this suit, Sun claimed that the closure was not under the WARN Act as the shutdown took place due to an unforeseeable business circumstance, which exempts companies from complying with the Act. The exemption states that the 60-day notice is not required if the closing is caused by business circumstances that were not reasonably foreseeable as of the time that notice would have been required. In order to qualify for the exception, the defendant must prove two elements: that the circumstances complained were unforeseeable and caused the mass layoff or shutdown.

Sun Pharmaceutical Industries Receives US FDA Approval for New Drug Application for its Extended Release Version of minocycline HCI

Sun Pharmaceutical Industries announced that its supplementary new drug application (sNDA) for its extended release version of minocycline HCI has been approved by the US FDA. It will be marketed under the brand name Ximino, which is approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

Sun Pharmaceutical Industries Limited Recommends Dividend for the Year Ended March 31, 2015

The board of directors of Sun Pharmaceutical Industries Limited at their meeting held on August 11, 2015, recommended payment of dividend of INR 3 per equity share of INR 1 each of the company for the year ended March 31, 2015, subject to the approval of the members at the ensuing AGM of the company to be held in around end of October 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUNP:IN 898.95 INR +12.50

SUNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cipla Ltd/India 682.15 INR +22.30
Endo International PLC $78.70 USD -0.30
Hospira Inc $89.93 USD +0.01
Mylan NV $50.37 USD -1.12
Perrigo Co PLC $185.42 USD -2.77
View Industry Companies
 

Industry Analysis

SUNP

Industry Average

Valuation SUNP Industry Range
Price/Earnings 56.0x
Price/Sales 7.4x
Price/Book 7.8x
Price/Cash Flow 40.2x
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUN PHARMACEUTICAL INDUS, please visit www.sunpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.